Skip to main content
Fig. 3 | BMC Pulmonary Medicine

Fig. 3

From: Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis

Fig. 3

Day 85 TDI responders by patient subgroup. The odds ratios for revefenacin versus placebo was statistically significant (p < 0.05) for the following subgroups: FEV1 30%–< 50% predicted, and > 75 years. CI confidence intervals; CV cardiovascular; FEV1 forced expiratory volume in 1 s; GOLD Global Initiative for Chronic Obstructive Lung Disease; LABA long-acting ß agonist; ICS inhaled corticosteroids; ITT intention-to-treat; TDI transition dyspnea index

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us